These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

98 related items for PubMed ID: 17926464

  • 1. [Recovery of polyclonial hemopoiesis in females with chronic myeloid leukemia with a complete cytogenetic response].
    Ermakova TA, Chelysheva EIu, Turkina AG, Sokolova MA, Zakharova AV, Danil'cheva ES, Misiurin AV.
    Ter Arkh; 2007; 79(8):13-6. PubMed ID: 17926464
    [Abstract] [Full Text] [Related]

  • 2. Molecular remission in chronic myeloid leukemia patients with sustained complete cytogenetic remission after imatinib mesylate treatment.
    Colombat M, Fort MP, Chollet C, Marit G, Roche C, Preudhomme C, Reiffers J, Praloran V, Mahon FX.
    Haematologica; 2006 Feb; 91(2):162-8. PubMed ID: 16461299
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Discontinuation of imatinib therapy after achievement of complete molecular response in a Ph(+) CML patient treated while in long lasting complete cytogenetic remission (CCR) induced by interferon.
    Breccia M, Diverio D, Pane F, Nanni M, Russo E, Biondo F, Frustaci A, Gentilini F, Alimena G.
    Leuk Res; 2006 Dec; 30(12):1577-9. PubMed ID: 16630657
    [Abstract] [Full Text] [Related]

  • 5. No significance of derivative chromosome 9 deletion on the clearance kinetics of BCR/ABL fusion transcripts, cytogenetic or molecular response, loss of response, or treatment failure to imatinib mesylate therapy for chronic myeloid leukemia.
    Kim DH, Popradi G, Sriharsha L, Kamel-Reid S, Chang H, Messner HA, Lipton JH.
    Cancer; 2008 Aug 15; 113(4):772-81. PubMed ID: 18543309
    [Abstract] [Full Text] [Related]

  • 6. [Prognosis factors in imatinib mesilate therapy in patients with a chronic phase of Ph-positive chronic myeloid leukemia: data from a multicenter non-randomized trial in Russia].
    Zaritskiĭ AIu, Lomaia EG, Vinogradova OIu, Druzhkova GA, Kolosheĭnova TI, Loria SS, Pospelova TI, Krylova IV, Kruglov SS, Kuznetsov SV, Chelysheva EIu, Abakumov EM, Sokolova MA, Nemchenko IS, Zakharova ES, Goriacheva SR, Kolosova LIu, Vakhrusheva MV, Liamkina AS, Chernova OA, Machiulaĭtene ER, Ivanova VL, Udal'eva VIu, Shneĭder TV, Ogorodnikova IuS, Zhuravlev VS, Zakharova AV, Martynkevich IS, Domracheva EV, Afanas'ev BV, Abdulkadyrov KM, Kovaleva LG, Khoroshko ND, Turkina AG.
    Ter Arkh; 2007 Aug 15; 79(8):17-22. PubMed ID: 17926465
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Detection of BCR-ABL gene mutations in Philadelphia chromosome positive leukemia patients resistant to STI-571 cancer therapy.
    Chien JH, Tang JL, Chen RL, Li CC, Lee CP.
    Leuk Res; 2008 Nov 15; 32(11):1724-34. PubMed ID: 18603297
    [Abstract] [Full Text] [Related]

  • 9. Achievement of complete molecular responses in late chronic phase chronic myeloid leukaemia patients treated with pulsed imatinib while in minimal residual disease.
    Breccia M, Cannella L, Stefanizzi C, Santopietro M, De Cuia R, Diverio D, Alimena G.
    Leuk Res; 2009 May 15; 33(5):645-8. PubMed ID: 19062090
    [Abstract] [Full Text] [Related]

  • 10. Imatinib mesylate therapy in chronic myeloid leukemia patients in stable complete cytogenic response after interferon-alpha results in a very high complete molecular response rate.
    Alimena G, Breccia M, Luciano L, Quarantelli F, Diverio D, Izzo B, De Angelis B, Mancini M, Latagliata R, Carmosino I, Nanni M, Picardi M, Rotoli B, Mandelli F, Pane F.
    Leuk Res; 2008 Feb 15; 32(2):255-61. PubMed ID: 17692911
    [Abstract] [Full Text] [Related]

  • 11. Cytogenetic and molecular responses and outcome in chronic myelogenous leukemia: need for new response definitions?
    Kantarjian H, O'Brien S, Shan J, Huang X, Garcia-Manero G, Faderl S, Ravandi-Kashani F, Verstovsek S, Beth Rios M, Cortes J.
    Cancer; 2008 Feb 15; 112(4):837-45. PubMed ID: 18085610
    [Abstract] [Full Text] [Related]

  • 12. Emergence of clonal cytogenetic abnormalities in Ph- cells in some CML patients in cytogenetic remission to imatinib but restoration of polyclonal hematopoiesis in the majority.
    Bumm T, Müller C, Al-Ali HK, Krohn K, Shepherd P, Schmidt E, Leiblein S, Franke C, Hennig E, Friedrich T, Krahl R, Niederwieser D, Deininger MW.
    Blood; 2003 Mar 01; 101(5):1941-9. PubMed ID: 12411298
    [Abstract] [Full Text] [Related]

  • 13. Mean cell volume can be an early predictor for the cytogenetic response of chronic myeloid leukemia patients treated with imatinib?
    Song MK, Chung JS, Seol YM, Kim SG, Shin HJ, Choi YJ, Cho GJ.
    Leuk Res; 2009 Nov 01; 33(11):1459-62. PubMed ID: 19446878
    [Abstract] [Full Text] [Related]

  • 14. [Detection of ABL kinase domain point mutations in chronic myeloid leukemia patients receiving imatinib treatment].
    Ouyang Z, DU QF, Liu XL, Zhang S, Zhu HQ, Gong JM, Song LL, Ouyang LY, Liu Z.
    Nan Fang Yi Ke Da Xue Xue Bao; 2008 May 01; 28(5):704-6. PubMed ID: 18504184
    [Abstract] [Full Text] [Related]

  • 15. [Chronic myelogenous leukemia in cessation of therapy after sustained CCR with interferon].
    Usuki K, Kanda Y, Iijima K, Iki S, Hirai H, Urabe A.
    Rinsho Ketsueki; 2003 Dec 01; 44(12):1161-5. PubMed ID: 14978932
    [Abstract] [Full Text] [Related]

  • 16. Case report and literature review: a rare patient with chronic myeloid leukemia and chronic lymphocytic leukemia.
    Bhagavathi S, Borromeo V, Desai H, Crisan D.
    Ann Clin Lab Sci; 2008 Dec 01; 38(4):405-9. PubMed ID: 18988937
    [Abstract] [Full Text] [Related]

  • 17. Complete response to imatinib mesylate treatment in a 12-month-old patient with chronic myeloid leukemia.
    Arancibia AM, Bendit I, Epelman S.
    Pediatr Blood Cancer; 2008 May 01; 50(5):1078. PubMed ID: 18085674
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Chronic phase of ETV6-ABL1 positive CML responds to imatinib.
    Kawamata N, Dashti A, Lu D, Miller B, Koeffler HP, Schreck R, Moore S, Ogawa S.
    Genes Chromosomes Cancer; 2008 Oct 01; 47(10):919-21. PubMed ID: 18615681
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.